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ISOLATED human polymorphonuclear leukocytes (PMNL)
stimulated by platelet activating factor (PAF), leukotriene
B (LTB4) or opsonized zymosan (OZ) released adenosine
measured by thermospray high performance liquid chro-
matography mass spectrometry in the cell-free super-
natants. Stimulation by PAF or LTB4 resulted in a bell-
shaped concentration-effect curve; 5 10
-7 M PAF, 10
-8
M LTB and 500 Itg m1-10Z induced peak adenosine
release, thus cytotoxic concentrations did not elevate ade-
nosine level in the supernatants. Therefore adenosine
release was characteristic of viable cells. As calculated
from concentration-effect curves, the rank order of potency
for adenosine release was PAF > LTB > OZ. These re-
suits suggest that adenosine, when bound specifically to
membrane receptor sites, may initiate signal transduction,
and, in co-operation with other inflammatory mediators,
may modulate phagocyte function, e.g. production of
chemoluminescence (CL).
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Introduction
Platelet activating factor (PAF) is a phospholipid
autacoid implicated as mediator in the pathogenesis
of inflammation, thrombosis, immune disorders,
septic shock and a great variety of physiological and
pathophysiological conditions. 1’2 PAF as second
messenger of diverse injurious stimuli releases
eicosanoids and superoxide anions from leukocytes,
macrophages and endothelial cells.
Leukotrienes (LTs) are metabolites of ar-
achidonic acid (AA) formed by 5’-lipoxygenase.
One leukotriene, LTB4, is a potent chemotactic and
aggregating agent released from polymorpho-
nuclear leukocytes (PMNL). 4’5 LTB4 is also
involved in a variety of pathophysiological
processes, including y-interferon production.
Phagocytosis induced by opsonized zymosan
(OZ) is one of the most widely used models for
testing the function of stimulated PMNL.
Engulfment of particles via Fc, CR1 and CR3
receptors involves marked changes in cellular
metabolism, leading to degranulation and produc-
tion of superoxide anions.
Adenosine is a natural nucleoside known to
regulate various cellular functions, including
neurotransmission and local circulation.
1 These
effects of adenosine appear to be mediated by two
separate subtypes of binding sites, i.e., A and a2
receptors.
1 By interacting with one of these
receptor subtypes, adenosine can initiate a trans-
membrane signal which then may inhibit or
(C) 1992 Rapid Communications of Oxford Ltd
stimulate adenylate cyclase via A1 or A2 receptors,
respectively. A third adenosine recognition site,
termed the P site, located on the catalytic subunit
of adenylate cyclase, is activated by relatively high
concentrations of adenosine.
2 Near micromolar
concentrations of adenosine, interacting with A2
receptors, have been shown to inhibit PMNL
functions.
13
The present experiments were designed to study
the production and release of adenosine from
PMNL stimulated by PAF, LTB4 and OZ. The
results obtained suggest that adenosine released
from PMNL may induce inhibitory action, which
then, as a regulatory feedback signal, may protect
the phagocytes from irreversible damage due to
overstimulation during the inflammatory process.
Materials and Methods
Materials: Acetonitrile (HPLC grade, Baker Chemi-
cals, D/isseldorf, Germany), adenosine, bovine
serum albumin (BSA), 2-chloroadenosine, luminol
(5-amino-2,3-dihydro-1,4-phthalazinedione, Sigma
Chemicals, St. Louis, MO), dextran (molecular
mass 70 kDa, Macrodex) and zymosan (Mannozym,
Human Serobacteriological Institute, Budapest,
Hungary), Ficoll (Pharmacia Fine Chemicals,
Uppsala, Sweden), LTB4 dissolved in 99.5% ethanol
(Calbiochem, Lucerne, Switzerland), PAF (Bachem,
Bubendorf, Switzerland), TC-199 medium (Parker
medium, Institute of Hygiene, Budapest, Hungary),
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trypan blue (Reanal, Budapest, Hungary), Uromiro
(Bracco Chimica, Milan, Italy) were used, PAF
was dissolved in phosphate-buffered saline (PBS),
containing 1 mg ml-1 of BSA.
Separation of cells" Heparinized venous blood was
obtained from healthy donors. After removal of
mononuclear cells by Ficoll-Uromiro density
gradient centrifugation, the neutrophil-rich pellet
was sedimented by dextran. Residual erythrocytes
were lysed by hypotonic saline (0.45%). The final
cell suspension consisted of 95% PMNL and 5%
mononuclears but no red blood cells.
14
Measurement of adenosine" A thermospray high perfor-
mance liquid chromatography mass spectroscopy
(TSP-HPLC-MS)15’6 was used to determine adeno-
sine concentrations in cell-free supernatants of
PMNL stimulated with various concentrations of
PAF, LTB4 or OZ. 7’18 Proteins in 1 ml cell-free
supernatants were precipitated by addition of
acetonitrile (1"10, v/v) and subsequent centrifuga-
tion at 1500 g for 10 min. Aliquots of acetonitrile
solution, 25 #1 of each, were injected directly
onto the HPLC column. HPLC was carried out
using a Water C 18 Nova-Pak RP column
(15 x 0.40 cm I.D.) on a Model 640 gradient
controller and Model U6K injector. A linear
gradient from 20.5% to 70% acetonitrile in 0.05 M
aqueous ammonium acetate (1 mlmin-) was
used. The water for HPLC was Milli-Q quality.
Sample ionization was achieved by thermospraying
the HPLC eluent into a VG-TRIO-2 quadripole
mass spectrometer (VG MassLab, UK) via a VG
thermospray/plasmaspray interface. The ion source
temperature was held at 200C, TSP probe
temperature was 210C. Adenosine shows a base
peak corresponding to the [M+HI
+ ion at m/z 268.
The mass spectrometer monitored the eluent
continuously at m/z 268.
Measurement of chemiluminescence" 2 106 PMNL were
incubated in the presence of 5 x 10
-7 M PAF,
dissolved in PBS/BSA, and/or with 2-chlor-
oadenosine in various experimental conditions at
37C for 60 min. Chemiluminescence ofPMNL was
measured in PBS at a final volume of 1 ml in the
presence of 10
-7 M luminol using a Nuclear
Chicago/300 liquid scintillation counter (Searle,
Indianapolis, IN) in the off coincidence mode. 19’2
Viability of cells" Viability was determined by the
trypan-blue exclusion test to detect the percentage
of viable cells at the beginning of the experiments
and to check the cytotoxic elect of PAF, LTB4 and
OZ at the end of incubation with these stimulating
agents.
2
Statistical analysis: Data are expressed as means __+
standard deviation (SD). Each adenosine determi-
nation was carried out in triplicate samples.
Data were statistically analyzed by the tailed
Student’s t-test. Differences were considered
significant when p was less than 0.05.
Results
Adenosine release: Adenosine release was studied in
samples of 2 106 PMNL m1-1 incubated with
various concentrations of PAF, LTB4 and OZ in
TC-199 medium under 5% CO2 for 30 and 60 min.
Adenosine content in the supernatants was
determined by TSP-HPLC-MS, and measured
values were compared to that obtained in
non-stimulated cell suspensions. In supernatants
obtained from non-stimulated cells adenosine
concentrations were below the limit of detectability.
PAF at 10
-5 M concentration resulted in a well
established adenosine release; maximal production
was induced by 5 10
-7 M, whereas after
exposure to 10
-4 M no detectable adenosine
concentrations were measured in the supernatants
(Figure 1). The cytotoxic effect of 10
-4 M PAF was
85%. This bell-shaped concentration-eect curve
indicates that extracellular appearance of adenosine
may be due to intracellular metabolic processes
rather than cell damage.
LTB4 also increased adenosine content of
supernatants in a similar manner (Figure 2). Peak
release was observed at 10
-8 M. The highest
concentration of adenosine released by LTB4-
stimulated PMNL remained, however, below the
values that were produced by PAF. This
corresponded to a lower cytotoxicity of LTB4; the
cytotoxic effect of 10-5 M LTB4 was only 20%. The
calculated ratio of adenosine production, i.e., total
adenosine released by PAF/total adenosine released
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FIG. 1. Release of adenosine from human PMNL stimulated by various
concentrations of PAF. 2 x 106 PMNL m1-1 were incubated in TC-199
medium at 37C for 60 min. PAF was dissolved in PBS/BSA and 50 #1
was added to each sample to reach its final concentration in ml.
Adenosine concentrations in cell-free supernatants were determined by
TSP-HPLC-MS; means +_ SD, n 3.
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FIG. 2. Release of adenosine from human PMNL stimulated by various
concentrations of LTB4.2 106 PMNL m1-1 were incubated in TC-199
medium at 37C for 60 min. LTB4 was dissolved in 99.5% ethanol then
diluted with the incubation medium. The solvent itself, added in 3 #1 to
the ml incubation medium, had no effect on adenosine release.
Adenosine concentrations in cell-free supernatants were determined, by
TSP-HPLC-MS; means _4- SD, n 3.
by LTB4, in the concentration ranges of 10 -9 to
10
-4 M or 10
-1 to 10-s M PAF or LTB4
respectively was 2.25, indicating an efficacy for PAF
higher than for LTB4.
The kinetics of adenosine release were de-
termined in PMNL stimulated with 5 x 10-r M
PAF, 10
-8 M LTB4 and 500 #g m1-1 OZ at 37C
for 30 and 60 min. This entirely non-cytotoxic
concentration of OZ was used since it was shown
to induce the highest CL of PMNL.
22 As shown in
Table 1, adenosine concentrations in the super-
natants of cell suspensions stimulated for 30 min
were lower than that measured after 60min
stimulation. Stimulation by OZ for 30 min did not
produce any detectable elevation of adenosine
concentration. The rank order of potency for
adenosine release was PAF > LTB4 > OZ.
Chemiluminescence: The inhibition by adenosine of CL
in PMNL was demonstrated in transfer experi-
ments. Supernatants of PMNL incubated in the
presence of 5 10 -7 M PAF, containing approx-
imately 400nM adenosine, were transferred to
unstimulated cells, and the luminol induced
Table 1. Adenosine concentrations in the supernatants of
human PMNL stimulated by PAF, LTB4 and opsonized zymosan
Concentration of adenosine, nM means _+ SD
Stimulation by
Incubation, PAF LTB4 opsonized zymosan
min 5 x 10-7 M 10-8 M 500#gm1-1
30 405 + 89 183 + 81 ND
60 533+151 351 +113 103+41
2 x 106 PMNL m1-1 were incubated in TC-199 medium at
37C. Adenosine concentrations in the cell-free supernatants
were determined by TSP-HPLC-MS; n 3, PMNL were used
from three healthy donors, ND not detectable.
Table 2. Effect of PAF and 2-chloroadenosine (2-c-Ado) on
the chemiluminescence of human PMNL
Group number of emitted photons,
cpm means -I- SD
PMNLin PBS/BSA
60 min (control)
2 PMNLin PBS/BSA
60 min plus PAF
3 PMNLplusPAF
in PBS/BSA, 60 min
4 PMNLplussupernatant (3)
plus PAF
5 PMNLin PBS/BSA
60 min plus 2-c-Ado
6 PMNLin PBS/BSA
60 min plus 2-c-Ado and PAF
1152 _+ 143
2114 + 342*
1320 + 211
1457 + 256
1085 + 117
1188 + 196
2 x 106 PMNL were incubated at 37C. PAF dissolved in
PBS/BSA and 2-chloro-adenosine (2-c-Ado) were added at
final concentrations of 5 x 10-7 M and 10-6 M, respectively.
In transfer experiments the cell-free supernatant of PAF
stimulated (adenosine containing) PMNL (sample 3) was added
to freshly prepared, unstimulated cells (sample 4). In sample 6,
PAF was added to the cells after preincubation of PMNL with
2-c-Ado for 10 min. Chemiluminescence, measured in a
scintillation counter by the off coincidence mode, was induced
by 5 x 10-7 M PAF added to the cells at the end of incubation,
except when the background chemiluminescence of PMNL
incubated alone (sample 1) or in the presence of 2-c-Ado
(sample 5) was determined; n 4, PMNL of the same healthy
donors were used in four separate experiments. *p < 0.01 as
compared to control.
amplification of CL in these cells was measured, or
PAF induced CL was determined in the presence of
2-chloroadenosine, a stable analogue of adenosine.
Preincubation of PMNL with PAF at 37C for
60min produced adenosine concentrations that
were able to inhibit the CL of freshly added PAF
when transferred to unstimulated cells. This
stimulation was almost as intense as that was seen
after addition of 10
-6 M 2-chloroadenosine (Table
2).
Discussion
Beyond the lipid character, common features in the
effects of PAF and LTB4 are the induction of
chemotaxis, aggregation and superoxide anion
production in PMNL. 1’23’24 This study shows that
both PAF and LTB4 release adenosine from PMNL,
although the effect of PAF is more marked than
that of LTB4. The dit:ference may be explained by
the fact that PAF can also release LTB4,3’18 thus
adenosine release induced by PAF presumably
includes that released by LTB4. Regardless of
distinct receptor binding sites for PAF and LTB4
on PMNL membrane,<24-26 these findings point to
the similarity of signal transduction triggered by the
two autacoids, suggesting their involvement in a
common pathway of the inflammatory process.
The particles of OZ are internalized by PMNL
via Fc, CR1 and CR3 receptors leading to
degranulation of specific azurophil granules and
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production of superoxide anion.
27 In our study,
OZ proved to be the least effective in releasing
adenosine from human PMNL. Stimulated PMNL
produce PAF and LTB4 at picomolar concentra-
tions,
28 and this may explain the finding that
adenosine concentrations are much lower in
supernatants of cells stimulated with OZ than in
supernatants stimulated with higher, micromolar
concentrations of exogenous PAF or LTB4. This
can also be reflected by the kinetics of adenosine
production in stimulated cells. While 30min
stimulation was found to be optimal for production
of adenosine by PAF or LTB4, this incubation
period was insufficient in OZ-activated PMNL17’29
to detect a measurable amount of adenosine in the
supernatant, while 60 min stimulation resulted in a
well established increase of adenosine concentra-
tion. Accordingly, adenosine production by PAF
and LTB4 was also more marked after 60 min than
at 30 min stimulation.
The preparation of a completely platelet free
human PMNL suspension is practically impossible.
The rate of platelet contamination in our PMNL
suspensions was ordinarily 1:1. The estimated
amount of adenosine possibly derived from
aggregated platelets was 50nM. To aggregate
platelets but not neutrophils, ADP was added to
cells suspended in TC-199 medium, and adenosine
release was measured in the supernatants 60 min
later (data not shown). From these results the
conclusion can be drawn that the major part of
adenosine released by PAF, LTB4 and OZ is derived
from PMNL.
Adenosine is produced by the breakdown of
intracellular ATP, and an increased consumption of
ATP results from the stimulation of phagocytes via
the pathway of ATP synthesis from ADP:
2ADP ATP 4- AMP (1)
5’-nucleosidase AMP adenosine
22 (2)
We assume that, at a certain degree of ATP
depletion in activated cells, this process may lead to
accumulation of adenosine at nearly micromolar
concentrations in the extracellular space, because
some adenosine molecules may escape from the
rapid breakdown by adenosine deaminase located
on the external surface of cells.
3 These molecules
may then bring important signal transduction for
regulating the function of surrounding cells.
Adenosine binding A2 receptor subtypes and P sites,
has been shown to inhibit PMNL functions, e.g.
intracellular killing or generation of oxygen derived
free radicals.
31 As previously described,
11 this effect
is related to an activation of adenylate cyclase with
a concomitant elevation of intracellular cAMP level.
Intracellular cAMP raised by eicosanoids, in
particular prostacyclin (PGI2) has been shown to
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downregulate eicosanoid production in platelets32’33
and vascular endothelium.
34 PAF has been shown
to release AA by conversion not only to the
lipoxygenase product LTB4,3’18 but also through the
cyclooxygenase pathway to prostaglandin E2
(PGE2)
35 and PGI2 .36 All these events have been
shown to augment the number of emitted photons
in luminol induced CL.
37 Eicosanoid synthesis by
itself is therefore associated with increased light
emission
38 and indomethacin can block such Ct.
39
Consequently, the elevation of intracellular cAMP
by PGs, the endproducts of AA metabolism, is
accompanied by decreased CL as a consequence of
feedback inhibition brought about either directly as
a result of decreased precursor conversion or
through the NADPH oxidase system.
4 Thus, CL
of phagocytes can be modulated not only by
adenosine released from stimulated cells, but also
by AA and its biologically highly active end-
products depending upon the stage of their
production. At the same time, a great variety of
interactions may occur among inflammatory medi-
ators, for example, adenosine can block LT
synthesis.
41 An elevated intracellular cAMP level,
induced by either adenosine,
42 PGE241 or PAF
43
may be an important signal transduction to
downregulate eL,
44 thus being a sensitive marker
for the metabolic and functional state of phago-
cytes. Another important aspect of this auto-
regulatory feedback network is that cAMP has also
been implicated in the inhibition of PAF release.
45
On the other hand, the extracellular nucleotides,
such as ATP, ADP and AMP, may induce the
opposite effect, i.e., stimulation of adhesiveness and
other functions of PMNL.
46
This regulatory and inhibitory role for exogen-
ously applied and endogenously released adenosine
has been described in stimulated PMNL.
47-49 Our
data confirm these observations and support the
view that production and release of adenosine may
regulate the function of activated PMNL and
other phagocytes. In the autocatalytic feedback
network of inflammatory mediator release,s adeno-
sine may therefore be regarded as an important
signal molecule downregulating the production of
PAF, LTB4 and other lipid mediators, and through
this mechanism activated PMNL and other
phagocytes may be protected from potentially
irreversible damage due to overstimulation, s1’52
This modulatory action, however, takes place in
co-operation with other mediators, mainly AA
derivatives.
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